FDA
approval
· 2023-06-07
FDA Approved: BUPRENORPHINE AND NALOXONE — Supplemental Application (Actavis Pharma, Inc.)
Summary
FDA approved a supplemental application for Actavis Pharma’s generic buprenorphine/naloxone product for the treatment of opioid dependence. The product provides…
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
SUPPL AP for BUPRENORPHINE AND NALOXONE (BUPRENORPHINE AND NALOXONE)